Skip to main content

Table 2 Clinical data in IPMN with and without invasive carcinoma

From: The association between serum ferritin levels and malignant intraductal papillary mucinous neoplasms

  Invasive carcinoma
(n = 23)
Noninvasive carcinoma (n = 128) p
Age 61.52 ± 11.40 63.60 ± 9.09 0.51
Size 3.95 ± 1.85 3.64 ± 2.00 0.27
Sex (male/female) 15/8 80/48 0.80
Type    <  0.01
  Main-duct 9 15  
  Brach-duct 3 70  
  Mixed 11 43  
Location    0.24
  Head-neck 17 78  
  Body and Tail 6 50  
CEA (ng/ml) 7.11 ± 8.05 3.06 ± 1.98 0.006
  CEA > 5.0 5 14 0.11
CA19–9 (U/ml) 160.00 ± 568.57 29.40 ± 70.66 0.004
  > 37 10 19 0.001
Ferritin (ng/ml) 387.66 ± 465.68 254.79 ± 235.41 0.18
  > 232 12 48 0.19
PD diameter 0.98 ± 0.49 0.54 ± 0.36 < 0.001
Chronic cholecystitis 10 46 0.49
Pancreatitis 0 3 1.0
Abdominal Symptoms 9 58 0.58
Diabetes 7 18 0.05
Lymph node metastasis (yes vs no) 2 0 0.02
Extrapancreatic expansion 5 0 < 0.01
Mural nodule 9 8 < 0.01
  1. CA 19–9 carbohydrate antigen 19–9; CEA carcinoembryonic antigen; MPD main pancreatic duct